CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Wakamoto Pharmaceutical Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Wakamoto Pharmaceutical Co Ltd
2-2-2, Nihombashihon-cho
Phone: +81 332790371p:+81 332790371 CHUO-KU, TKY  103-8330  Japan Ticker: 45124512
Business Summary
WAKAMOTO PHARMACEUTICAL CO., LTD. is a Japan-based company mainly engaged in the manufacture and sale of ethical drugs such as gastrointestinal drugs and non-prescription drugs. The Company operates through four business segments. The Pharmaceuticals segment is involved in the manufacture and sale of innovator drugs, generic drugs and optiaid series supplements mainly in the ophthalmic field, as well as the commission of production and the sale of diagnostic drugs and raw materials in Japan. The Healthcare segment sales its core product Kawakami Wakamoto, the Avantbise series of medicated toothpastes that promote bad breath prevention based on evidence and Avantbise Oral Tablet mainly in the mail order business. The International segment is involved in the business related to the export of products and raw materials mainly in Asia and Europe, as well as the new license in and out business. The Real Estate Leasing segment is involved in the rental business of Coredo Muromachi.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20233/31/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
2833 Medicinal chemicals and botanical products
5122 Drugs, drug proprietaries, and druggists' sundries
6513 Operators of apartment buildings

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Representative Director ArataIgarashi 65 4/1/2022 6/1/2011
Senior Executive Officer, Manager of Business Planning NoboruYamazaki 6/1/2023 6/1/2023
Managing Director, Chief Director of Healthcare Business KimihikoSato 58 6/1/2024 6/24/2014
10 additional Officers and Directors records available in full report.

Business Names
Business Name
4512
Wakamoto Pharmaceutical Co., Ltd.

General Information
Number of Employees: 292 (As of 3/31/2023)
Outstanding Shares: 34,706,762 (As of 12/31/2023)
Shareholders: 6,992
Stock Exchange: TYO
Fax Number: +81 332796450


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, April 28, 2024